Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
LSL Pharma Group Inc ( (TSE:LSL) ) has shared an update.
LSL Pharma Group has obtained U.S. FDA certification for the manufacturing of ophthalmic ointments at its Steri-Med Pharma facility, following a successful inspection confirming full compliance with current Good Manufacturing Practices. This certification underpins FDA approval of its ophthalmic product Avaclyr, to be marketed in the U.S. by Fera Pharmaceuticals, and opens the door for LSL Pharma to produce and potentially commercialize additional ophthalmic ointments in the American market, bolstering its competitive position, revenue diversification and plans to expand manufacturing capacity to meet U.S. demand for specialized ophthalmic products.
More about LSL Pharma Group Inc
LSL Pharma Group Inc. is a Canadian integrated pharmaceutical company specializing in the development, manufacturing and commercialization of sterile ophthalmic pharmaceutical products, alongside pharmaceutical, cosmetic and natural health products in solid, semi-solid and liquid dosage forms. Through subsidiaries including Steri-Med Pharma Inc., LSL Laboratory Inc., Virage Santé Inc., Dermolab Pharma Ltd., Du-Var Laboratory Inc. and Juno OTC Inc., the company leverages certified facilities and technical expertise to deliver high-quality, regulatory-compliant healthcare solutions.
Average Trading Volume: 82,205
Technical Sentiment Signal: Buy
Current Market Cap: C$58.79M
For detailed information about LSL stock, go to TipRanks’ Stock Analysis page.